banda transcan 2 2016ul

Title: New technologies for early detection of HLA loss leukemia relapse after allogeneic hematopoietic stem cell transplantation, and identification of relevant risk factors.


Project Coordinator:
Luca VAGO (italy), San Raffaele Hospital, Milan
(and Katharina FLEISCHHAUER, Germany)


Project Partners:
Dietrich BEELEN (Germany) Universitätsklinikum Essen, Essen
Didier BLAISE (France) Institut Paoli Calmettes, Marseille
Martin BORNHÄUSER (Germany) Universitäsklinikum Carl Gustav Carus, Dresden
Mohamad MOHTY (France) Hopital Saint Antoine, Paris
Anon NAGLER (Israel) Chaim Sheba Medical Center, Tel Hashomer


Project Abstract:
Acute Myeloid Leukemia (AML) and related cancers of the blood system can be cured by hematopoietic stem cell transplantation from healthy allogeneic donors (allo-HSCT), due to the capacity of immune cells from the donor to recognize and attack mismatched human leukocyte antigen (HLA) molecules on the patient’s leukemia. However, the success of allo-HSCT in curing AML is hampered by disease recurrence, which is frequently due to selective loss of the patient-specific HLA by recurring leukemia posttransplantation (“HLA loss relapse”). In this project, 6 of the major European HSCT centres (each involved in translational research and clinical activity) will join in a combined bench-to-bedside effort aimed at developing new methodologies for early detection of HLA loss relapse, determining its frequency in different transplant settings, and identifying clinical and immunogenetic risk factors for the development of this leukemia variants. Results expected from this study will provide a unique platform for dissemination of novel technical and clinical know-how within Europe, and facilitate a significant step forward in the early detection and cure of leukemia.

(Project funded under JTC 2012)


TRANSCAN News

Launch of the call: JTC 2021
The new TRANSCAN-3 project consortium is launching the first Joint Transnational Call for proposals, co-funded by the European Commission, on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is the new project funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 17 guests and no members online